Imagin Medical – The Next Generation Ultrasensitive Imaging Solutions for Early Detection and Treatment of Cancer

 

Imagin Medical Inc. is a medical imaging company positioned to radically improve the way physicians detect cancer through the use of endoscopes. The Company is developing the i/Blue Imaging System which they believe will help reduce the recurrence of bladder cancer. This technology will increase urologists’ ability to remove all cancerous cells through an endoscope (cystoscope) by dramatically improving the ability to visualize suspicious masses. Imagin’s system’s unique combination of optical/laser technologies projects white light and near-infrared fluorescence through the scope to increase the imaging sensitivity, greatly reduce the dosage of chemical agents and blend the images so that only one monitor is required during surgery. The i/Blue Imaging System can be seamlessly adapted to most endoscope on the market today.

 

The company’s products are based on the invention of Dr. Stavros Demos from the Lawrence Livermore National Laboratory (LLNL). Dr. Stavros worked in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer, for more than five years to prove feasibility. IME has entered into a partnership with the LLNL and UC Davis to complete additional clinical evaluations that will support their FDA submission.

 

 

Latest News Release

Imagin's i/Blue Imaging System Prototype Redesign Begins

Imagin Medical Inc.'s optical product-design firm, Optel Inc., will begin the redesign of the i/Blue imaging system prototype for manufacturability and commercialization. The redesign will be concurrent with the first in-human research study using the i/Blue prototype that is anticipated to begin shortly at the University of Rochester Medical Center.

 

With its unique expertise in the manufacture and miniaturization of optical systems, Optel integrates optics, mechanics, electronics, and software into user-friendly, cost-effective products. Optel will work with Imagin to bring the alpha prototype of its state-of-the-art, optics-based i/Blue Imaging System through three phases of development: proof of concept, functional unit, and the redesigned verified unit ready for manufacturing.

 

The i/Blue system will be a mobile device, 70% smaller than the current prototype that can be easily moved between operating rooms and physicians' offices. First proof-of-concept product samples are expected to be available late in the calendar first quarter of 2018. The device will be highly manufacturable and cost effective, with a modular design that will be the basic platform for Imagin's i/Blue Imaging System to expand from bladder cancer detection to other minimally invasive surgical procedures requiring improved visualization.

 

The i/Blue Imaging System is highly sensitive and is estimated to be greater than 100 times more precise than currently available systems. It is expected to highlight cancer lesions and put the cancer in context in less than 10 minutes, compared to the current standard of one hour. It is anticipated this procedure will be more comprehensive, improve outcomes, and expand the market. Early detection may reduce the recurrence of bladder cancer.

 

Jay Eastman, Optel's founder, received his B.S. and Ph.D. at The Institute of Optics at the University of Rochester. He previously held positions as the Omega Laser System project manager, and Director of the Laboratory of Laser Energetics (LLE), where development of the i/Blue Imaging System alpha prototype was completed. Dr. Eastman commented, "Combining our electronics design expertise with the fact that the i/Blue prototype was developed at Rochester's LLE and will be tested in the operating rooms at the University of Rochester Medical Center will greatly facilitate rapid product development."

 

Critical to Imagin Medical, Optel will ensure that the i/Blue Imaging System will be in compliance with the requirements of the FDA, Good Manufacturing Practices (GMP), European medical device standard ISO 13485, and other international compliance requirements.

 

"With the urology community looking for improved bladder-cancer detection, this is an exciting time as the human research study begins and the product redesign is underway," said Jim Hutchens, Imagin's President and CEO.

 

About Imagin Medical Inc.

 

Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth-most prevalent in the United States, and the most costly cancer to treat due to a greater than 50-per-cent recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.


For further information, contact:


Jim Hutchens,

President & CEO


Telephone: (617) 571-6006
Email: jhutchens@imaginmedical.com

 

Legal Notice / Disclaimer

 

This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment.

 

Richard Mills has based this document on information obtained from sources he believes to be reliable but which has not been independently verified.

 

Richard Mills makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Richard Mills only and are subject to change without notice. Richard Mills assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission.

 

Furthermore, I, Richard Mills, assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.


To contact us please email rick@aheadoftheherd.com

Ahead of the Herd
www.aheadoftheherd.com